Spanish Drugmaker Grupo Zeltia (ZEL: MC) is Approaching a material Catalyst this year in the form of the read-out from its Phase II Study of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer, Say Analysts at Edison Investment Research..
...